Human study · Supplements / medicine · 8 Sept 2026
Caffeine may flip an ancient cellular switch linked to slower aging
Source: ScienceDaily
What the research found
Study (fission yeast). Queen Mary University of London’s Charalampos Rallis and John-Patrick Alao report in Microbial Cell that caffeine appears to act through AMPK, an energy sensor, rather than directly on TOR, influencing growth, stress resistance, and DNA repair in Schizosaccharomyces pombe. AMPK is also a target discussed in metformin aging research. Yeast is not a human longevity trial, and the paper does not prove coffee extends human life. Educational cell-biology notes, not a caffeine protocol.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34